Carcinoid syndrome mimicking irritable bowel syndrome: don't fall into the trap.

IF 3.3 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Sara Massironi, Camilla Gallo, Marianna Franchina, Caterina Sbarigia, Maura Corsetti, Silvio Danese
{"title":"Carcinoid syndrome mimicking irritable bowel syndrome: don't fall into the trap.","authors":"Sara Massironi, Camilla Gallo, Marianna Franchina, Caterina Sbarigia, Maura Corsetti, Silvio Danese","doi":"10.1080/17474124.2025.2557245","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Carcinoid syndrome (CS) is a complex condition caused by the systemic release of bioactive substances from neuroendocrine neoplasms (NENs), particularly small bowel tumors (sbNENs). Its symptoms-flushing, abdominal pain, and diarrhea-often resemble irritable bowel syndrome (IBS), resulting in misdiagnosis and delayed therapy.</p><p><strong>Areas covered: </strong>This review examines the pathophysiology of CS, especially serotonin overproduction and its effects on gut motility and secretion. The overlap between CS and IBS is analyzed, with emphasis on diagnostic pitfalls and warning signs. Distinctive features include \"dry\" flushing without sweating, typical of CS, versus \"wet\" or emotional flushing in IBS or anxiety. Poor response to standard IBS treatments and symptom exacerbation after specific foods or alcohol may also indicate CS. The utility of biomarkers such as 5-HIAA and imaging modalities including intestinal ultrasound and 68 Ga-DOTATATE PET/CT is discussed. A comprehensive literature search was conducted using PubMed, Embase, and the Cochrane Library for English-language studies published between January 2000 and March 2024.</p><p><strong>Expert opinion: </strong>Early recognition of subtle differences and red-flag symptoms, combined with appropriate use of biomarkers and imaging, can minimize misdiagnosis. Timely identification of CS may improve patient outcomes by enabling earlier and more effective interventions.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1119-1132"},"PeriodicalIF":3.3000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2025.2557245","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Carcinoid syndrome (CS) is a complex condition caused by the systemic release of bioactive substances from neuroendocrine neoplasms (NENs), particularly small bowel tumors (sbNENs). Its symptoms-flushing, abdominal pain, and diarrhea-often resemble irritable bowel syndrome (IBS), resulting in misdiagnosis and delayed therapy.

Areas covered: This review examines the pathophysiology of CS, especially serotonin overproduction and its effects on gut motility and secretion. The overlap between CS and IBS is analyzed, with emphasis on diagnostic pitfalls and warning signs. Distinctive features include "dry" flushing without sweating, typical of CS, versus "wet" or emotional flushing in IBS or anxiety. Poor response to standard IBS treatments and symptom exacerbation after specific foods or alcohol may also indicate CS. The utility of biomarkers such as 5-HIAA and imaging modalities including intestinal ultrasound and 68 Ga-DOTATATE PET/CT is discussed. A comprehensive literature search was conducted using PubMed, Embase, and the Cochrane Library for English-language studies published between January 2000 and March 2024.

Expert opinion: Early recognition of subtle differences and red-flag symptoms, combined with appropriate use of biomarkers and imaging, can minimize misdiagnosis. Timely identification of CS may improve patient outcomes by enabling earlier and more effective interventions.

类癌综合征模仿肠易激综合征:不要落入陷阱。
类癌综合征(CS)是由神经内分泌肿瘤(NENs),特别是小肠(sbNENs)全身释放生物活性物质引起的一种复杂疾病。诸如潮红、腹痛和腹泻等症状通常与肠易激综合征(IBS)相似,导致经常误诊和延误治疗。涉及领域:本综述探讨了CS的病理生理机制,聚焦类癌综合征(CS)由于胃肠道症状重叠而经常被误诊为肠易激综合征(IBS)。G对血清素过量产生及其对胃肠运动和分泌的影响。它强调了CS和IBS之间的临床重叠,强调了诊断挑战和危险信号。特别注意区分典型的CS的“干性”潮红(不出汗)和与肠易激综合征或焦虑相关的“湿性”或情绪性潮红。对标准IBS疗法缺乏反应以及特定食物或酒精引发的症状也是重要的诊断线索。强调了生物标志物(如5-HIAA)和肠道超声、68 Ga-DOTATATE PET/CT等成像方式的作用。使用PubMed、Embase和Cochrane图书馆对2000年1月至2024年3月间发表的英语研究进行了全面的文献检索。专家意见:识别细微的区别特征,早期识别危险症状,并应用有针对性的诊断工具可以减少误诊,改善结果,并支持对CS的及时干预。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Expert Review of Gastroenterology & Hepatology
Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
6.80
自引率
2.60%
发文量
86
审稿时长
6-12 weeks
期刊介绍: The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书